Date: 2021-03-17 Your Name: Jiayu Yao Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicateSpecifications/Comments (e.g., if payments were made to you or to you institution) none (add rows as needed)	our
--	-----

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bo or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or non financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Yongchao Wang Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
--	---

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bo or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or non financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Tiebo Mao Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

needed)			Specifications/Comments (e.g., if payments were made to you or to your institution)
---------	--	--	---

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bo or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or non financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Yiyi Liang Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

needed)			Specifications/Comments (e.g., if payments were made to you or to your institution)
---------	--	--	---

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bo or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or non financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Xiao Zhang Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
--	---

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bo or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or non financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Haiyan Yang Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

needed)			Specifications/Comments (e.g., if payments were made to you or to your institution)
---------	--	--	---

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bo or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or non financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Jiong Hu Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with Specifications/Comments whom you have this (e.g., if payments were made to you or to your relationship or indicate institution) none (add rows as needed)	ır
--	----

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bc or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or nor financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Feng Jiao Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with whom you have thisSpecifications/Comments (e.g., if payments were mad relationship or indicate institution) none (add rows as needed)	le to you or to your
--	----------------------

 All support for the present _____None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

3 Royalties or licenses	None
4 Consulting fees	None
5 Payment or honoraria lectures, presentations speakers bureaus, manuscript writing or educational events	5,
6 Payment for expert testimony	None
7 Support for attending meetings and/or trave	
8 Patents planned, issue pending	ed orNone
9 Participation on a Dat Safety Monitoring Bc or Advisory Board	
10 Leadership or fiducian role in other board, society, committee or advocacy group, paid unpaid	
11 Stock or stock option:	sNone
12 Receipt of equipment materials, drugs, mec writing, gifts or other services	lical
13 Other financial or nor financial interests	None

I declared that I have no conflicts of interest to this work. I declare that I do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Jiujie Cui Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Shanghai "Rising Stars of Medical Talent" Youth Development Programme [2019]72	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
-			
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
_	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. Cui reports grant from "Rising Stars of Medical Talent" Youth Development Programme [2019]72 of Shanghai, China.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-03-17 Your Name: Liwei Wang Manuscript Title: A Review of Safety management of first-line platinum-based chemotherapy and maintenance olaparib in patients with BRCA mutated advanced pancreatic cancer Manuscript number (if known): TCR-20-3478-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	grant 81572315 and 81874048 (to Liwei Wang) from National Natural Science Foundation of China	
		Time frame: past	36 months
2	Grants or contracts from	None	
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Current for other ding	Nene	
/	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
-			
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	None	
11	Stock or stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	None	
15	financial interests		

Dr. Wang reports grant 81572315 and 81874048 (to Liwei Wang) from National Natural Science Foundation of China.

Please place an "X" next to the following statement to indicate your agreement: